ZA71 Stock Overview A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Larimar Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Larimar Therapeutics Historical stock prices Current Share Price US$3.80 52 Week High US$12.20 52 Week Low US$3.76 Beta 0.61 1 Month Change -36.13% 3 Month Change -30.91% 1 Year Change -8.65% 3 Year Change -59.36% 5 Year Change n/a Change since IPO -73.07%
Recent News & Updates
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-Term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia Dec 17
Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 Nov 19
New major risk - Revenue and earnings growth Oct 30
Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study Sep 20
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index Jul 03
United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia May 31 See more updates
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-Term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia Dec 17
Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 Nov 19
New major risk - Revenue and earnings growth Oct 30
Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study Sep 20
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index Jul 03
United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia May 31 Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. May 11
New major risk - Revenue and earnings growth Apr 03
Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia Mar 12
New minor risk - Shareholder dilution Feb 15 Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million. Feb 15
Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.
Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia Feb 12
Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors Oct 05
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial Jul 26
Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes Jul 18
Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia May 16
Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer Feb 08
High number of new and inexperienced directors Nov 16
CEO, President & Director recently bought €100k worth of stock Sep 20
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients Sep 15
Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration Aug 12
High number of new and inexperienced directors Apr 27
Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022 Apr 13
Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director Apr 12
Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program Feb 15
Independent Director recently bought €419k worth of stock Jul 05
Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601 May 26
Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors May 22
Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia May 21
Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia May 12
New 90-day low: €15.00 Jan 23
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update Dec 10
New 90-day high: €18.90 Dec 04
New 90-day high: €18.50 Nov 16
New 90-day high: €15.42 Oct 14
Larimar Therapeutics Announces Formation of Scientific Advisory Board Oct 14
New 90-day high - €13.82 Sep 15
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index Jul 04 Shareholder Returns ZA71 DE Biotechs DE Market 7D -3.6% 1.2% -0.3% 1Y -8.7% -14.3% 7.0%
See full shareholder returns
Return vs Market: ZA71 underperformed the German Market which returned 7% over the past year.
Price Volatility Is ZA71's price volatile compared to industry and market? ZA71 volatility ZA71 Average Weekly Movement 12.5% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: ZA71's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ZA71's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Show more Larimar Therapeutics, Inc. Fundamentals Summary How do Larimar Therapeutics's earnings and revenue compare to its market cap? ZA71 fundamental statistics Market cap €231.73m Earnings (TTM ) -€62.23m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ZA71 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$64.77m Earnings -US$64.77m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 19:28 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Larimar Therapeutics, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Joel Beatty Baird Samantha Lynn Semenkow Citigroup Inc Samantha Lynn Semenkow Citigroup Inc
Show 10 more analysts 
